Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: Frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production

Cancer Research

Volumn 60, Issue 9, 2000, Pages 2527-2534

  Fusetti, Lisa ^a   Pruneri, Giancarlo ^a   Gobbi, Alberto ^a   Rabascio, Cristina ^a   Carboni, Nadia ^b   Peccatori, Fedro ^a   Martinelli, Giovanni ^a   Bertolini, Francesco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MATURATION; CELL VIABILITY; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DENDRITIC CELL; DIABETES MELLITUS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SOLID TUMOR; VASCULAR ENDOTHELIUM; XENOTRANSPLANTATION;

ACUTE DISEASE; AGED; ANIMALS; APOPTOSIS; BONE MARROW; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; LEUKEMIA, MYELOID; LYMPHOKINES; LYMPHOMA, NON-HODGKIN; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034194582     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bonnet, D., and Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 3: 730-737, 1997.
2. Hudson, W. A., Li, Q., Le, C., and Kersey, J. H. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia (Baltimore), 12: 2029-2033, 1998.
3. Baersch, G., Mollers, T., Hotte, A., Dockhorn-Dworniczak, B., Rube, C., Ritter, J., Jurgens, H., and Vormoor, J. Good engraftment of B-cell precursor ALL in NOD-SCID mice. Klin. Paediatr., 209: 178-185, 1997.
4. Steele, J. P., Clutterbuck, R. D., Powles, R. L., Mitchell, P. L., Horton, C., Morilla, R., Catovsky, D., and Millar, J. L. Growth of human T-cell lineage acute leukemia in severe combined immunodeficiency (SCID) mice and non-obese diabetic SCID mice. Blood, 90: 2015-2019, 1997.
5. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med., 1: 27-31, 1995.
6. Perez-Atayde, A. R., Sallan, S. E., Tedrow, U., Connors, S., Allred, E., and Folkman, J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol., 150: 815-821, 1997.
7. Pruneri, G., Bertolini, F., Soligo, D., Carboni, N., Cortelezzi, A., Ferrucci, P. F., Buffa, R., Lambertenghi-Deliliers, G., and Pezzella, F. Angiogenesis in myelodys-plastic syndromes. Br. J. Cancer, 81: 1398-1401, 1999.
8. Foss, H. D., Araujo, I., Demel, G., Klotzbach, H., Hummel, M., and Stein, H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J. Pathol., 183: 44-50, 1997.
9. Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F., and Dammacco, F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93: 3064-3073, 1999.
10. Fiedler, W., Graeven, U., Ergun, S., Verago, S., Kilic, N., Stockschlader, M., and Hossfeld, D. K. Vascular endothelial growth factor, a possible paracrine factor in human acute myeloid leukemia. Blood, 89: 1870-1875, 1997.
11. Bellamy, W. T., Richter, L., Frutiger, Y., and Grogan, T. M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res., 59: 728-733, 1999.
12. Ferrara, N., and Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev., 18: 4-25, 1997.
13. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., and Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 2: 1096-1103, 1996.
14. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., and Carbone, D. P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92: 4150-4166, 1998.
15. Tokunaga, T., Nakamura, M., Oshika, Y., Ohnishi, Y., and Ueyama, Y. Is xenotransplantability of human colon cancers in SCID mice affected by angiogenic factors? J. Natl. Cancer Inst., 90: 400-401, 1998.
16. Bertolini, F., Paolucci, M., Peccatori, F., Cinieri, S., Agazzi, A., Ferrucci, P. F., Cocorocchio, E., Goldhirsch, A., and Martinelli, G. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br. J. Haematol., 106: 504-509, 1999.
17. Conn, G., Soderman, D. D., Schaeffer, M. T., Wile, M., Hatcher, V. B., and Thomas, K. A. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proc. Natl. Acad. Sci. USA, 87: 1323-1327, 1990.
18. Philpott, N. J., Turner, A. J. C., Scopes, J., Westby, M., Marsch, J. C. W., Gordon-Smith, E. C., Dalgleish, A. G., and Gibson, F. M. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood, 87: 2244-2251, 1996.
19. Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., and Seed, B. Tumor induction of VEGF promoter activity in stromal cells. Cell, 94: 715-725, 1998.
20. Grunstein, J., Roberts, W. G., Mathieu-Costello, O., Hanahan, D., and Johnson, R. S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res., 59: 1592-1598, 1999.
21. Okada, F., Rak, J. W., Croix, B. S., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA, 95: 3609-3614, 1998.
22. Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., Horner, J. W., Cordon-Cardo, C., Yancopoulos, G. D., and DePinho, R. A. Essential role for oncogenic Ras in tumour maintenance. Nature (Lond.), 400: 468-472, 1999.
23. Holash, J., Masonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., and Wiegand, S. J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (Washington DC), 284: 1994-1998, 1999.
24. Solanilla, A., Grosset, C., Lemercier, C., Dupouy, M., Mahon, F. X., Schweitzer, K., Reiffers, J., Weksler, B., and Ripoche, J. Expression of Flt3-ligand by the endothelial cell. Regulation by IL-1α, glucocorticoids, IFN-α, MIP-1α and TGFβ. Key role in the proliferation of primitive hematopoietic progenitors. Blood, 92: 580a, 1998.
25. Namikawa, R. SCID-hu mice as a model for the study of human malignancies. In: M. G. Roncarolo, B. Peault, and R. Namikawa (eds.), Human Hematopoiesis in SCID Mice, pp. 157-170, New York: Springer-Verlag, 1995.
26. Bohem, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
27. Harris, A. L. Antiangiogenesis for cancer therapy. Lancet, 349: 13-15, 1997.
28. Kim, K. J., Li, B., Winter, J., Armanini, M., Gillett, N., Philips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
29. 121. Cancer Res., 55: 5296-5301, 1995.
30. Fong, T. A. T., Shawver, L. K., Li, S., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, Y., Risau, W., Ullrich A., Hirth, K. P., and McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.